NCT00104286

Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors

An Open-Label, Single-Arm, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With an Advanced Solid Malignancy

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (planned)
• Sponsor: SGX Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, single-arm, open-label, single-center study to establish the recommended infusion schedule for Troxatyl™ administered as a continuous infusion for 2-5 days to subjects with solid tumors.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	Troxatyl™ (Cytotoxic Chemotherapeutic)

Timeline

• Start date: 2003-01-01
• Completion: 2005-11-01
• First posted: 2005-02-25
• Last updated: 2006-11-03

Locations

1 site across 1 country: United States